Prostate Cancer
Half of the prostate cancer found in Korea in the 2010s was high-risk, and the rural share was higher still
50.6 percent high-risk across a decade, with the low-risk share falling from 11.4 to 7.6 percent. 55.4 percent of high-risk cases came from rural areas against 47.7 percent from urban ones.
Reported by Andrew Cho
Reporter
- Sources
- 2 cited
- Published
- Reading time
- 6 minutes
In short
In a nationwide chart-abstracted cohort of 27,075 prostate cancer cases from 51 Korean general hospitals with 200 or more beds, diagnosed in 2010, 2012, 2014, 2016, 2018 and 2020 and representing 37.9 percent of the 71,403 patients in national cancer statistics for those years, high-risk disease was the most prevalent category at 50.6 percent and remained so consistently nationwide, the low-risk share including potentially low-risk cases fell from 11.4 percent in 2010 to 7.6 percent in 2020, and 55.4 percent of high-risk cases arose in rural areas against 47.7 percent in urban areas (P < 0.001).
Key takeaways
- 27,075 cases from 51 general hospitals represented 37.9 percent of the 71,403 patients in Korean national cancer statistics for the indexed years.
- High-risk prostate cancer was the most prevalent category at 50.6 percent across the decade.
- The low-risk share, including potentially low-risk cases, fell from 11.4 percent in 2010 to 7.6 percent in 2020.
- High risk was defined as PSA above 20 ng/mL, clinical stage cT3a or higher, or Gleason group 4 or above.
- High-risk disease was the most prevalent category in 9 of the 17 administrative regions.
- 55.4 percent of high-risk cases arose among rural residents against 47.7 percent among urban residents (P < 0.001).
- The authors read the urban-rural gap as a disparity in access to early detection rather than a difference in disease biology.
Prostate cancer has a reputation as the cancer men die with rather than of, built on Western screening populations where most of what gets found is small and slow. Korean national data does not describe that disease. Half of what was found here in the 2010s was high-risk at the moment of diagnosis.
50.6%
What high-risk meant here
The criteria were the universal guideline definitions in use through the 2010s: prostate-specific antigen above 20 ng/mL, clinical stage cT3a or beyond, or Gleason grade group 4 or higher. Meeting any one of those puts a man in the high-risk category. These are not marginal thresholds — a PSA above 20 is roughly five times the level that usually prompts a biopsy.
The reason this had not been reported before is worth noting, because it says something about what national databases can and cannot do. Korea's insurance-based registry records that a man has prostate cancer and what was done about it. It does not record his PSA, his clinical stage or his Gleason grade. Producing a risk distribution required abstracting charts from 51 hospitals by hand.
The direction of travel
Low-risk disease, counting potentially low-risk cases with it, fell from 11.4 percent of diagnoses in 2010 to 7.6 percent in 2020. Over a decade in which testing became more available, not less, the share of mild disease being caught went down by a third.
The rural gap
High-risk disease was the most prevalent category in 9 of 17 administrative regions, and 55.4 percent of high-risk cases came from rural residents against 47.7 percent from urban ones. The authors attribute this to differences in access to early detection, and the alternative explanations are thin: there is no reason for prostate cancer to be biologically more aggressive outside cities in a population this genetically homogeneous.
One limit cuts against reading the rural figure as too clean. The cohort was drawn from hospitals with 200 or more beds, which are themselves concentrated in cities, so rural men in this dataset are those who reached a large hospital. If anything that selects for the better-connected end of the rural population, which would understate rather than exaggerate the gap.
Sources
- 1
Ko YH, Kim SW, Son NH
Incidence of High-Risk Prostate Cancer in Korea: Insights From Real-World Data Between 2010 and 2020Journal of Korean Medical Science 2026;41(14):e10
doi:10.3346/jkms.2026.41.e10 · PMID:41978922
https://doi.org/10.3346/jkms.2026.41.e10 - 2
Ko YH, Kim SW, Son NH
Active surveillance could apply to one-quarter of Korean prostate cancer cases: Insights from a 27,075-patient cohortProstate International 2026;14(2):127-131
doi:10.1016/j.prnil.2025.12.004 · PMID:42382553
https://doi.org/10.1016/j.prnil.2025.12.004
Related
News · Prostate Cancer
Only a quarter of Korean prostate cancer is eligible for active surveillance — and the share fell across the decade
27,075 biopsy-confirmed cases from 51 hospitals. Eligibility dropped from 27.6 percent in 2010 to 22.0 percent in 2020, and it varies by almost thirteen points depending on where a man lives.
Catherine Cho6 min read
News · Prostate Cancer
Men who had repeated PSA tests before diagnosis got surgery. Men who had none got hormone therapy
45.6 percent against 33.8 percent for surgery; 42.3 against 59.7 percent for hormone therapy. The cost difference came from how long the systemic treatment ran, not from its monthly price.
James Choi6 min read
News · Prostate Cancer
Same stage, same risk, different treatment: where a Korean man lives predicts what is done about his prostate cancer
Capital and urban residence meant more surgery for localised disease and more intensified systemic therapy for metastatic disease. Non-capital and rural residence meant hormone therapy alone — and the association survived adjustment for age, PSA, grade and stage.
James Choi6 min read